Compare BOLT & DTSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOLT | DTSS |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 9.0M |
| IPO Year | 2021 | 2015 |
| Metric | BOLT | DTSS |
|---|---|---|
| Price | $3.97 | $0.82 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $34.00 | N/A |
| AVG Volume (30 Days) | 16.1K | ★ 17.7K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | N/A | ★ N/A |
| Revenue | $7,695,000.00 | ★ $71,616,820.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $133.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.07 | ★ 198.70 |
| 52 Week Low | $3.75 | $0.58 |
| 52 Week High | $7.20 | $2.50 |
| Indicator | BOLT | DTSS |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 48.36 |
| Support Level | $3.90 | $0.80 |
| Resistance Level | $4.46 | $0.84 |
| Average True Range (ATR) | 0.24 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 39.10 | 61.54 |
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Datasea Inc is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).